NETJETS
For the 23rd consecutive year, NetJets, the global leader in private aviation, proudly announces its partnership with Art Basel. To highlight its commitment to the arts, NetJets will collaborate with French abstract artist Silvère Jarrosson to create a new art collection exclusively for NetJets that will be displayed at the Art Basel shows in Basel, Paris and Miami Beach.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521442854/en/
Silvère Jarrosson, credit Julien Benhamou
Born and raised in Paris, Jarrosson trained as a ballet dancer at the renowned Opera National de Paris at only 10 years old but transitioned into abstract painting a decade ago. His background in ballet is seen throughout his motion and fluidity while creating his works of art. Represented by contemporary art agency Studio Artera in Paris, Jarrosson is known for using his whole body to make his art – as he moves or ‘dances’ with the canvas to create his signature acrylic pieces.
At only 31 years of age, Jarrosson has received widespread praise and has had his work showcased globally. His art is featured in prestigious institutions such as the Villa Medici in Rome, the Unterlinden Museum in Colmar, the Lambert Collection in Avignon, the Crédit du Nord Collection, the Mobilier National and the Opera National de Paris, among others.
Jarrosson’s project created for NetJets, entitled “Inner Horizons”, offers Owners – the individuals and businesses who are clients of NetJets’ private jet ownership model – captivating insight into his world of poetic immersion, where his spectators become part of the creative inspiration for his shows and projects. His work will be featured in NetJets' exclusive area within the Collectors Lounge. Accessible only by Owners, it will offer a secluded space for guests to enjoy hospitality throughout the show week of Art Basel in Basel. The show aims to merge external travel experiences made possible by NetJets with inner travel experiences created by Jarrosson’s art.
Patrick Gallagher, President of Sales, Marketing & Service, commented: “We are delighted with this partnership. We admire the synergy from the movement Silvère uses to create his art pieces. His beautiful artwork truly moves observers who watch him paint. Despite coming from different industries, we align in our passion to both create and capture exceptional experiences for others. As many of our Owners are deeply interested in fine art, we believe this partnership will be both inspiring and exciting as Silvère’s career continues to flourish.”
Globally recognised for its revolutionary shared ownership business model, NetJets’ impeccable reputation spans more than 60 years and has reshaped how people fly private. NetJets proudly maintains and operates over 1,000 aircraft, grants access to more than 5,000 airports and employs over 8,300 private aviation professionals to deliver outstanding service.
About NetJets
Originally incorporated in 1964 as Executive Jet Airways, NetJets has been setting – and exceeding – industry standards for over 60 years. Today, NetJets is proud to be a Berkshire Hathaway company known for its unwavering commitment to safety and service. NetJets’ portfolio of distinctive companies, encompassing NetJets, Executive Jet Management, QS Partners and QS Security, offers a variety of customisable travel solutions, including shared ownership, lease and jet card options, aircraft management, private jet chartering, brokerage and acquisition services and specialised security services. This comprehensive suite of solutions is why so many of the world’s most discerning travellers choose NetJets generation after generation. It is also because NetJets has the largest, most diverse private jet fleet in the world, which grants anytime access to even the most remote destinations across the globe. To learn more about the leader in private aviation, visit netjets.com today.
About Studio Artera
Studio Artera is an art and talent agency based in Paris that supports the finest visual artists.
We represent artists and integrate art in all contexts by creating meaningful artistic collaborations with brands, companies, cultural institutions, and cities. Driven by the desire to reach an ever-wider audience through art, we build artistic narratives with our clients to inspire millions of people around the world.
Clients of Studio Artera include Louis Vuitton, Prada, Levi’s, Bombay Sapphire, the Hoxton Group, the City of Paris, Château Charmail, and Viva Technology.
To learn more about us, please visit www.studioartera.com
About Art Basel
Founded in 1970 by gallerists from Basel, Art Basel today stages the world’s premier art shows for Modern and contemporary art, sited in Basel, Miami Beach, Hong Kong, and Paris. Defined by its host city and region, each show is unique, which is reflected in its participating galleries, artworks presented, and the content of parallel programming produced in collaboration with local institutions for each edition. Art Basel’s engagement has expanded beyond art fairs through new digital platforms and initiatives such as the Art Basel and UBS Global Art Market Report. Art Basel’s Global Media Partner is The Financial Times. For further information, please visit artbasel.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521442854/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release
IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release
Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom